These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8368736)

  • 41. Ophthalmologic evaluation in patients undergoing immunization with melanoma-associated antigens.
    Kim CJ; Chan CC; Rosenberg SA
    J Immunother; 1999 Mar; 22(2):182-3. PubMed ID: 10093043
    [No Abstract]   [Full Text] [Related]  

  • 42. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
    Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
    J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.
    Weide B; Pascolo S; Scheel B; Derhovanessian E; Pflugfelder A; Eigentler TK; Pawelec G; Hoerr I; Rammensee HG; Garbe C
    J Immunother; 2009 Jun; 32(5):498-507. PubMed ID: 19609242
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.
    Kaufman HL; Deraffele G; Mitcham J; Moroziewicz D; Cohen SM; Hurst-Wicker KS; Cheung K; Lee DS; Divito J; Voulo M; Donovan J; Dolan K; Manson K; Panicali D; Wang E; Hörig H; Marincola FM
    J Clin Invest; 2005 Jul; 115(7):1903-12. PubMed ID: 15937544
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
    Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
    J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Perspectives for immunization of HLA-A1 patients carrying a malignant melanoma expressing gene MAGE-1.
    Marchand M; Brasseur F; van der Bruggen P; Coulie P; Boon T
    Dermatology; 1993; 186(4):278-80. PubMed ID: 8513199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes.
    Kirkin AF; Dzhandzhugazyan K; Zeuthen J
    Exp Clin Immunogenet; 1998; 15(1):19-32. PubMed ID: 9619397
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Report of the International Consensus Conference on Human Melanoma Antigens, Lausanne, Switzerland, 12-14 November, 1992.
    Reisfeld RA
    Melanoma Res; 1993 Jun; 3(3):209-17. PubMed ID: 8104571
    [No Abstract]   [Full Text] [Related]  

  • 49. [Active specific immunotherapy of malignant melanoma].
    Lotem M; Shiloni E; Ingber A; Peretz T
    Harefuah; 1997 Aug; 133(3-4):122-6. PubMed ID: 9332080
    [No Abstract]   [Full Text] [Related]  

  • 50. Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal.
    Rosenthal R; Viehl CT; Guller U; Weber WP; Adamina M; Spagnoli GC; Heberer M; Zuber M
    J Am Coll Surg; 2008 Jul; 207(1):95-105. PubMed ID: 18589368
    [No Abstract]   [Full Text] [Related]  

  • 51. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).
    Loftus DJ; Castelli C; Clay TM; Squarcina P; Marincola FM; Nishimura MI; Parmiani G; Appella E; Rivoltini L
    J Exp Med; 1996 Aug; 184(2):647-57. PubMed ID: 8760818
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16.
    Vantomme V; Boël P; De Plaen E; Boon T; van der Bruggen P
    Cancer Immun; 2003 Dec; 3():17. PubMed ID: 14664500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The immunogenic properties of human melanomas and melanoma-associated antigens recognized by cytotoxic T lymphocytes.
    Zeuthen J; Dzhandzhugazyan K; Hansen MR; Kirkin AF
    Bratisl Lek Listy; 1998; 99(8-9):426-34. PubMed ID: 9810766
    [TBL] [Abstract][Full Text] [Related]  

  • 54. T cell-defined melanoma antigens: toward a tumour-specific immunotherapy of the disease.
    Parmiani G
    Melanoma Res; 1993 Dec; 3(6):391-3. PubMed ID: 7909243
    [No Abstract]   [Full Text] [Related]  

  • 55. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.
    Fukushima S; Hirata S; Motomura Y; Fukuma D; Matsunaga Y; Ikuta Y; Ikeda T; Kageshita T; Ihn H; Nishimura Y; Senju S
    J Immunother; 2009 Apr; 32(3):219-31. PubMed ID: 19242378
    [TBL] [Abstract][Full Text] [Related]  

  • 56. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?
    Campoli M; Ferrone S
    Expert Rev Vaccines; 2004 Apr; 3(2):171-87. PubMed ID: 15056043
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel immunotherapeutic approach to melanoma-bearing hosts with protein-transduction domain-containing immunogenic foreign antigens.
    Kanzaki M; Okamoto T; Mitsui H; Shibagaki N; Shimada S
    J Dermatol Sci; 2010 Nov; 60(2):84-94. PubMed ID: 20864317
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rational development of peptide vaccination in clinical oncology.
    Keiholz U; Scheibenbogen C; Theil E; Schadendorf D
    Onkologie; 2001 Apr; 24(2):174. PubMed ID: 11476074
    [No Abstract]   [Full Text] [Related]  

  • 59. Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro.
    Imro MA; Dellabona P; Manici S; Heltai S; Consogno G; Bellone M; Rugarli C; Protti MP
    Hum Gene Ther; 1998 Jun; 9(9):1335-44. PubMed ID: 9650618
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients.
    Takahashi T; Irie RF; Morton DL; Hoon DS
    Cell Immunol; 1997 Jun; 178(2):162-71. PubMed ID: 9225007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.